Trials / Recruiting
RecruitingNCT07479641
A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Test formulation of HRS-1893 tablet | Test formulation of HRS-1893 tablet, oral. |
| DRUG | Reference formulation of HRS-1893 tablet | Reference formulation of HRS-1893 tablet, oral. |
Timeline
- Start date
- 2026-04-14
- Primary completion
- 2026-06-01
- Completion
- 2026-07-01
- First posted
- 2026-03-18
- Last updated
- 2026-04-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07479641. Inclusion in this directory is not an endorsement.